Company news

Madrigal Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

January 5, 2023

Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program

December 20, 2022

Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

December 18, 2022

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th

December 17, 2022

Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results

November 2, 2022

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

August 30, 2022

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results

August 3, 2022

Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

June 24, 2022

Madrigal Pharmaceuticals Supports International NASH Day on June 9

June 5, 2022

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results

May 8, 2022

Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9

April 27, 2022

Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

March 8, 2022

Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

February 23, 2022

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

January 30, 2022

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st

January 29, 2022

Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer

January 9, 2022

Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

December 29, 2021

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

November 22, 2021

Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021

November 11, 2021

Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results

November 3, 2021

Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

October 3, 2021

Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update

August 4, 2021

Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer

August 1, 2021

Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

July 12, 2021

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom

June 29, 2021

Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021

June 24, 2021

Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference

May 20, 2021

Madrigal Pharmaceuticals to Present at RBC Capital Markets Virtual 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 8: 00 a.m. ET

May 17, 2021

Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer

May 17, 2021

Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights

May 5, 2021

Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

February 24, 2021

Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights

November 4, 2020

Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial

September 2, 2020

Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020

August 25, 2020

Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights

August 5, 2020

Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights

May 6, 2020

Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction

April 13, 2020

Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights

February 25, 2020

Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock

December 9, 2019

Madrigal Pharmaceuticals Announces Pricing of Secondary Offering

December 9, 2019

Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

November 10, 2019

Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights

November 5, 2019

← Newer news releases

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.